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Abstract
Aims Adult-onset autoimmune diabetes is prevalent in
China, in contrast to childhood-onset type 1 diabetes
mellitus. Islet autoantibodies are the most important
immune biomarkers to diagnose autoimmune diabetes. We
assayed four different islet autoantibodies in recently
diagnosed adult non-insulin-requiring diabetes Chinese
subjects to investigate the best antibody assay strategy for
the correct diagnosis of these subjects.
Methods LADA China study is a nation-wide multicenter
study conducted in diabetes patients from 46 university-
affiliated hospitals in China. Non-insulin-treated newly
diagnosed adult diabetes patients (n = 2388) were cen-
trally assayed for glutamic acid decarboxylase autoanti-
body (GADA), protein tyrosine phosphatase-2
autoantibody (IA-2A), and zinc transporter 8 autoantibody
(ZnT8A) by radioligand assay and insulin autoantibody
(IAA) by microtiter plate radioimmunoassay. Clinical data
were determined locally.
Results Two hundred and six (8.63 %) subjects were
autoantibody positive, of which GADA identified 5.78 %
(138/2388) of the total, but only 67 % (138/206) of the
autoimmune cases. IA-2A, ZnT8A, and IAA were found in
1.51, 1.84, and 1.26 % of the total study subjects, respec-
tively. When assaying three islet autoantibodies, the most
effective strategy was the combination of GADA, ZnT8A,
and IAA, which could identify 92.2 % (190/206) autoim-
mune diabetes patients. The clinical data showed that those
subjects with positive GADA had lower random C-peptide
than autoantibody negative subjects (P\ 0.05).
Conclusions As with Europeans, GADA is the dominant
autoantibody in this form of autoimmune diabetes in China,
but in contrast to Europeans, screening should include
other diabetes-associated autoantibodies.
Keywords Latent autoimmune diabetes of adults
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Introduction
Adult-onset autoimmune diabetes, associated with diabetes-
associated autoantibodies, often presents a similar clinical
phenotype to type 2 diabetes mellitus [1–3]. In patients with
this clinical phenotype, known as latent autoimmune dia-
betes of adults (LADA), b cell function decreases about
threefold faster than in type 2 diabetes [4]. As a result,
treatment needs to be implemented early and aggressively,
yet even on insulin therapy such patients can show worse
diabetes control [5–7]. Early therapeutic intervention
requires early diagnosis. For LADA, the diagnostic criteria
are controversial [8], but the widely accepted criteria from
the Immunology of Diabetes Society (IDS) are: (1) adult-
onset ([30 years), (2) insulin independency at diagnosis,
and (3) positive islet autoantibodies [2, 9].
Although the genetic background contributed a lot to the
onset of autoimmune diabetes, islet autoantibodies are the
most widely used in practice for the diagnosis [10]. Of the
most widely studied diabetes-associated autoantibodies in
LADA, islet cell antibody (ICA) [11] and glutamic acid
decarboxylase antibody (GADA) are the most prevalent in
Europeans [12, 13], though a proportion (about 6 %) only
have protein tyrosine phosphatase-2 antibody (IA-2A),
insulin autoantibody (IAA) [14, 15], or zinc transporter 8
autoantibody (ZnT8A) [16–18]. We found that adult-onset
autoimmune diabetes is prevalent in China when testing for
GADA [1], while ZnT8A augments the detection of LADA
in such Chinese patients [17]. We have noted differences in
the relative frequency of diabetes-associated autoantibod-
ies in European and Chinese childhood-onset type 1 dia-
betes mellitus patients [19]. To determine the most
appropriate islet autoantibody assaying strategy to identify
Chinese patients with LADA from adult-onset non-insulin
requiring diabetes patients, we assayed a large cohort for
four different diabetes-associated autoantibodies.
Research design and methods
LADA China is the first multicenter study to investigate
adult-onset autoimmune diabetes in recently diagnosed
phenotypic type 2 diabetes mellitus subjects in China in
terms of the epidemiology, clinical features, and
immunogenetic characteristics [1]. From this patient cohort
(n = 4880), we assayed 2388 non-insulin-requiring
recently diagnosed diabetes patients with sufficient serum.
The inclusion criteria included: (a) 1999 WHO diabetes
diagnostic criteria; (b) disease-onset not less than 30 years
old; (c) ascertained within 1 year from diagnosis;
(d) without ketoacidosis within 6 months after diagnosis;
(e) not on insulin therapy after diagnosis. The exclusion
criteria included: (a) not with secondary diabetes;
(b) women not in pregnancy; (c) not with tumor; (d) not
with severe heart, renal, or liver dysfunction. Demo-
graphics are shown in Table 1; clinical and laboratory data
including age, gender, height, weight, waist circumfer-
ences, hip circumferences, HbA1c, cholesterol
(CHOL),triglyceride (TG), LDL-chol, HDL-chol, and
fasting C-peptide (FCP) were collected locally with stan-
dardized methods by trained physicians and clinical bio-
chemistry laboratories.
All study subjects will centrally assayed for GADA, IA-
2A, ZnT8A, and IAA using standardized assays in a core
laboratory (Diabetes Center, Central South University).
The GADA, IA-2A, and ZnT8A were measured by radi-
oligand assay (RLA), and IAA was by microtiter plate
radioimmunoassay (RIA). In the Diabetes Autoantibody
Standardized Programme (DASP) 2009, all our assays
showed high sensitivity and specificity, i.e., GADA assay
(sensitivity 72 %, specificity 98 %), IA-2A assay (sensi-
tivity 66 %, specificity 99 %), ZnT8A assay (sensitivity
66 %, specificity 100 %), and IAA assay (sensitivity 42 %,
specificity 98 %), respectively.
Statistics
All analyses were performed by SPSS 13.0 software.
Results were shown as mean ± SD or as median (range) or
otherwise documented as positive cases, constituent ratio
or ratio. The unpaired t tests and analysis of variance for
multiple comparisons were used for normally distributed
data, and nonparametric tests were used for non-normally
distributed data. The difference between classified vari-
ables was tested using Chi-squared test or Fisher’s exact
test if the expected number of subjects in any cell was less
than 5. P values less than 0.05 were considered significant.
Results
Frequency of four islet autoantibodies in non-insulin
requiring adult-onset diabetes
Overall, in non-insulin requiring diabetes patients: posi-
tivity of GADA, IA-2A, ZnT8A and IAA were 5.8, 1.5,
1.8, and 1.3 % respectively. We stratified all these patients
by age, i.e., 30–39, 40–49, 50–59 and over 60 years; the
four islet autoantibodies did not show any statistical dif-
ferences between these age subgroups. However, in every
age subgroup, positivity for GADA is higher than for the
other three autoantibodies (P = or\ 0.01 for each)
(Table 2).
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Association of four islet autoantibodies in recently
diagnosed adult-onset non-insulin-requiring
diabetes
Of 2388 patients studied, 206 cases (8.6 %) had islet
autoantibodies, of which the majority (177/206; 85.9 %)
had a single positive autoantibody, more than had two
autoantibodies (17/206; 8.3 %), in turn, more than had
three autoantibodies (11/206; 5.3 %). Only one case had
all four islet autoantibodies. Overlap of positive autoan-
tibodies is shown in Fig. 1. Of note the majority of
autoantibody positive cases had GADA (138/206, 67 %)
(Fig. 2). Of 206 patients with autoantibodies, a combi-
nation assay with GADA plus one other autoantibody
could identify 80.1 % (with IAA), 79.6 % (with ZnT8A),
and 77.7 % (with IA2A), respectively (Fig. 2).The hier-
archy of likelihood for detecting autoimmune diabetes by
autoantibody testing in this cohort was
GADA[ IAA[ZnT8A[ IA2A. When assaying this
cohort with three islet autoantibodies, the most effective
strategy was the combination of GADA, ZnT8A, and
IAA, which could identify about 92.2 % (190/206) of
autoimmune diabetes patients of the total of 8.6 % with
autoantibodies (Fig. 2). We have investigated the
positivity of IAA, ZnT8A, and IA2A among high and low
GADA titer subgroups, and there was no statistical dif-
ferences for the presence of these autoantibodies in the
different GADA titer groups (data not shown).
Clinical features of subjects with autoantibodies
Compared with type 2 diabetes mellitus patients, clinical
and laboratory characteristics of adult-onset autoimmune
Table 1 Clinical characteristics
of antibody positive LADA and
antibody negative type 2
diabetes mellitus subjects
Ab (-) type 2 diabetes mellitus Ab (?) LADA
n 2182 206
Gender (M/F) 1250/932 129/77
Age (years) 51.2 ± 11.0 50.8 ± 11.6
BMI (kg/m2) 25.1 ± 3.8 24.6 ± 3.5
WHR 0.91 ± 0.07 0.91 ± 0.07
TG (mmol/L) 1.82 (0.39–34.13) 1.68 (0.50–14.99)a
CHOL (mmol/L) 5.05 ± 1.19 5.18 ± 1.18
HDL-C (mmol/L) 1. 27 ± 0.55 1.39 ± 0.74
LDL-C (mmol/L) 2.89 ± 0.94 2.89 ± 0.97
SBP (mmHg) 127.6 ± 18.1 125.6 ± 18.4
DBP (mmHg) 81.0 ± 18.5 80.2 ± 11.1
HbA1c (%) 8.77 ± 2.87 9.00 ± 2.52
Converted mean HbA1c (mmol/mol) 72 75
FCP (pmol/L) 657.3 (5.4–3210.4) 573.7 (59.44–1949.59)
a Compared with Ab (-) group. P\ 0.05
Table 2 Age stratification of
the non-insulin-requiring
diabetes patients with the
positivity for GADA, IA-2A,
ZnT8A, and IAA
Age (years) Cases GADA IA-2A ZnT8A IAA
30–39 373 6.17 % (23/373) 1.34 % (5/373)a 2.14 % (8/373)a 1.07 % (4/373)b
40–49 718 5.85 % (42/718) 2.09 % (15/718)b 2.51 % (18/718)a 1.11 % (8/718)b
50–59 753 5.58 % (42/753) 1.06 % (8/753)b 1.33 % (10/753)b 1.60 % (12/753)b
C60 544 5.70 % (31/544) 1.47 % (8/544)b 1.47 % (8/544)b 1.10 % (6/544)b
In total 2388 5.78 % (138/2388) 1.51 % (36/2388)b 1.84 % (44/2388)b 1.26 % (30/2388)b
Data were showed as percentage (positive cases/total cases), compared with the GADA positivity.




















Fig. 1 Venn diagram of GADA, IA-2A, ZnT8A, and IAA positivity
in adult non-insulin requiring autoimmune diabetes patients
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patients were similar, apart from having lower triglycerides
(Table 1). Patients with GADA had lower b cell function
as estimated by fasting C-peptide (FCP) [controls vs.
GADA (?): 657.3 (5.4–3210.4) vs. 519.3 (105.9–1648.0)
pmol/L, P\ 0.001], higher HDL-ch [controls vs. GADA
(?):1.27 ± 0.55 vs. 1.42 ± 0.82 mmol/L, P\ 0.05], and
lower SBP [controls vs. GADA (?): 127.6 ± 18.1 vs.
123.0 ± 17.2 mmHg, P\ 0.05] (Table 3). Though the
numbers were small, patients with adult autoimmune dia-
betes with single autoantibodies, when compared with type
2 diabetes mellitus patients, had significantly lower BMI
(with IA2A alone), lower triglycerides (with IA2A or IAA
alone), higher HDL (with IA2A alone), higher CHOL (with
ZnT8A alone), and higher WHR (with ZnT8A alo-
ne)(P\ 0.05 for each) (Table 3). Compared with GADA
(?) autoimmune diabetes subjects, patients with ZnT8A
had higher WHR and SBP (P\ 0.05 for each) (Table 3).
Conclusions
Our previous studies in childhood-onset type 1 diabetes
mellitus suggested that the pattern of islet autoantibodies in
Chinese patients is different from European patients [18].
In European childhood-onset type 1 diabetes mellitus
subjects, diabetes-associated autoantibodies are prevalent,
e.g., GADA (79 %), IA-2A (69 %), ZnT8A (64 %), and
IAA (70 %) [20]. In contrast, in Chinese patients the same
autoantibodies are less prevalent: GADA (53 %), IA-2A
(26 %), ZnT8A (24 %), and IAA (22 %) [18]. In both
populations, GADA was the most prevalent autoantibody.
However, it is well established that the pattern of autoan-
tibodies differs in European adult-onset, compared with
childhood-onset, autoimmune diabetes [18]. In particular,
IAA is prevalent in children but far less prevalent in adults,
while GADA is by far the most prevalent autoantibody in
adult-onset autoimmune diabetes [1, 21, 22]. Since such
autoimmune diabetes patients are easily misdiagnosed as
having type 2 diabetes mellitus, it is important to determine
the optimum screening strategy for them. This present
report is the first to describe the pattern of multiple dia-
betes-associated autoantibodies in non-insulin-requiring
adult-onset diabetes in a Chinese population.
In the European Action LADA study, 90 % of adult-
onset diabetes patients had GADA, while IA-2A and
ZnT8A only identified 10 % of the remaining cases [3]. In
the Italian NIRAD study, 96 % of adult-onset autoimmune
diabetes patients had GADA, the remainder being identi-
fied by IA-2A and ZnT8A [23]. In striking contrast, in this
present Chinese study, only 67 % of autoimmune diabetes
patients were GADA positive, though GADA was again the
dominant autoantibody. About 33 % of adult-onset
autoimmune diabetes Chinese patients were identified by
autoantibodies other than GADA, including IA2A, ZnT8A,
and IAA, a much higher frequency than that found in
Europe. Though the numbers are small, those Chinese
patients with diabetes-associated autoantibodies other than
GADA did show a range of clinical differences compared
with the type 2 diabetes mellitus cases, which is in line
with European adult-onset autoimmune diabetes and con-
sistent with these autoantibodies identifying a cohort of
patients clinically different from type 2 diabetes mellitus
[21].
Limitations of our study include the possibility that we
have detected false positives, despite the high specificity
for our autoantibody assays and the repetition of the pos-
itive assays to both limit that error and increase the assay
specificity. Despite the substantial numbers tested, the low
positivity of IA-2A, ZnT8A, and IAA also limits the power
of our analysis. Moreover, this present cohort probably
excludes patients with the more aggressive form of adult-
onset autoimmune diabetes, as we have excluded patients
on insulin therapy in order to estimate IAA. In summary,
while GADA detects about 90 % of autoimmune adult-
onset diabetes patients in Europe, our results indicate that
in China screening for diabetes-associated autoantibodies
should include autoantibodies other than GADA.
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Fig. 2 Histogram of different assay strategy for GADA, ZnT8A, IA-
2A, and IAA in adult-onset autoimmune diabetes. x axis stands for
different diabetes-associated islet autoantibodies combination strate-
gies. y axis stands for the percentage of patients with different assay
strategies in a total of 206 adult autoimmune diabetes
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Hospital, Fudan University (Shanghai); XinGao, Zhong-
shan Hospital, Fudan University (Shanghai); Yanbing Li,
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(Guangzhou); Huazhang Yang, Guangdong General
Hospital (Guangzhou); Shaoda Lin, the First Affiliated
Hospital,Shantou University (Shantou); Shenren Chen, the
Second Affiliated Hospital, Shantou University (Shantou);
Table 3 Clinical characteristics of GADA, IA-2A, ZnT8A, and IAA positive and autoantibody negative non-insulin required type 2 diabetes
mellitus subjects
Abs (-) GADA (?) IA-2A (?) GADA (-) ZnT8A (?) GADA (-) IAA (?) GADA (-)
n 2182 138 22 27 26
Gender (M/F) 1250/932 84/54 12/10 18/9 19/7
Age (years) 51.2 ± 11.0 50.48 ± 11.6 52.1 ± 12.3 49.56 ± 10.06 53.6 ± 12.7
BMI (kg/m2) 25.1 ± 3.8 24.7 ± 3.8 23.6 ± 2.5b 24.8 ± 3.1 24.6 ± 2.7
WHR 0.91 ± 0.07 0.90 ± 0.07 0.92 ± 0.06 0.94 ± 0.04ae 0.90 ± 0.06
TG (mmol/L) 1.82 (0.39–34.13) 1.70 (0.50–14.99) 1.54 (0.67–2.49)cd 1.73 (0.88–13.36) 1.64 (0.64–4.74)a
CHOL (mmol/L) 5.05 ± 1.19 5.19 ± 1.22 5.17 ± 1.07 5.56 ± 1.13a 4.87 ± 1.07
HDL-C (mmol/L) 1.27 ± 0.55 1.42 ± 0.82a 1.50 ± 0.42a 1.37 ± 0.68 1.28 ± 0.45
LDL-C (mmol/L) 2.89 ± 0.94 2.84 ± 1.01 2.99 ± 0.72 3.25 ± 1.02 2.82 ± 0.76
SBP (mmHg) 127.6 ± 18.1 123.0 ± 17.2a 124.0 ± 14.9 133.7 ± 23.4e 131.9 ± 16.3
DBP (mmHg) 81.0 ± 18.5 79.55 ± 11.0 80.3 ± 8.7 83.6 ± 13.0 80.2 ± 10.5
HbA1c (%) 8.77 ± 2.87 9.04 ± 2.39 10.18 ± 2.51 9.20 ± 2.16 7.48 ± 3.09
Converted Mean HbA1c
(mmol/mol)











Compared with Abs (-) group. a P\ 0.05, b P\ 0.01, c P\ 0.001; compared with GADA (?) group, d P\ 0.05, e P\ 0.01
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Medical University (Dalian); Yan Liu, The Norman
Bethune 1st hospital of Jilin University (Changchun);
HuanqiGe, The Norman Bethune 2nd hospital of Jilin
University (Changchun); Yadong Sun, People’s Hospital of
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Hospital of Fujian Medical University (Fuzhou); Hui-
juZhong, Xiangya Hospital of Central South University
(Changsha); Zhiguang Zhou, The Second Xiangya Hospital
of Central South University (Changsha); Jianying Liu, The
First Affiliated Hospital of Nanchang University (Nan-
chang); Jing Yang, The First Hospital of Shanxi Medical
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